Product Details:
|
Product Name: | Tirzepatide | Appearance: | White Freeze-dried Powder |
---|---|---|---|
Purity: | 99% | Grade: | Pharmaceutical Grade |
Specification: | 10mg/ Customized | MOQ: | 1 Box |
Packing: | Vial, Box | Trademark: | Green-Biotech |
Origin: | China | Paypment Ways: | Paypal, Western Union, Bank Transfer, Bitcoin |
High Light: | Retatrutide GLP-1 Peptides,GLP-1 Receptor Agonist Tirzepatide Peptides |
Product Name | Peptides |
Specification | 10mg/vial;10vials/box |
Grade | Pharmaceutical Grade |
Shelf Life | 2 years |
Purity | over 98% |
OEM/ODM | MOQ over 1 box |
Payment ways | Western Union, Alipay, bank transfer or Bitcoin |
Delivery | Delivery after receive the payment |
Shipping Time | Normally need take around 15 days |
Tirzepatide CAS 2023788-19-2 Retatrutide GLP-1 Peptides Powder For GLP-1 Receptor Agonist
What is Tirzepatide?
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.
Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.
We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg with those of semaglutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy.
Product Benefits:
· Helps slow food leaving your stomach
· Helps prevent your liver from making too much sugar
· Helps the pancreas produce more insul when your blood sugar levels are high
· Can help control blood glucose
· Can reduce hyperglycemia, especially after meals
· Can reduce fasting insul and fasting glucose
· Can reduce hemoglobin A1c
· Can decrease appetite and caloric intake, while inhibiting weight gain
· Has been shown to lower triglyceride levels and oxidative stress from high LDL
· Has been shown to help induce weight loss in obese patients with higher dosing
· Helps decrease leptin and increase leptin sensitivity
· Can increase the conversion of white fat to brown fat
Contact Person: Wendy YU
Tel: +8613227740219